Literature DB >> 20688085

Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats.

N V Cunha1, S B de Abreu, C Panis, S Grassiolli, F A Guarnier, R Cecchini, T L Mazzuco, P Pinge-Filho, M C Martins-Pinge.   

Abstract

AIMS: the purpose of the present work was to investigate the effect of cyclooxygenase-2 (COX-2) inhibition on the cardiovascular and inflammatory aspects promoted by monosodium glutamate (MSG)-induced obesity in rats. MAIN
METHODS: Neonatal Wistar male rats were injected with MSG (4 mg/g body weight ID) or equimolar saline (control). Treatment with celecoxib (50 mg/kg ip) or saline (0.9% NaCl ip) began at 60 days of age. At 90 days, all rats were anesthetized for catheterization of the femoral artery, and the mean arterial pressure (MAP) and heart rate (HR) were recorded once consciousness was regained. KEY
FINDINGS: MSG obese rats were hypertensive (MAP=138±4 mm Hg) compared with controls (MAP=118±2 mm Hg). After treatment with celecoxib, the hypertension was attenuated (MAP=126±2 mm Hg) in obese rats without changes in HR. The retroperitoneal and periepididymal fat weighed more in obese rats (Obese: Retro=7.08±0.51, Peri=6.36±0.81, CONTROL: Retro=3.60±0.46; Peri=3.24±0.42), but celecoxib did not alter these parameters. Plasma nitric oxide levels were not different between groups. However, the level of plasma prostaglandins, the immunohistochemical staining of COX-2 in cardiac tissue and plasma lipoperoxidation were higher in obese rats, and celecoxib attenuated these parameters. MSG produced liver steatosis that was also attenuated following celecoxib treatment. SIGNIFICANCE: Our data demonstrate an association between increased blood pressure and products of COX-2 in obese rats, suggesting a role for prostaglandins in the hypertensive and inflammatory aspects of MSG-induced obesity. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688085     DOI: 10.1016/j.lfs.2010.07.014

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Decreased oxidant profile and increased antioxidant capacity in naturally postmenopausal women.

Authors:  V J Victorino; C Panis; F C Campos; R C Cayres; A N Colado-Simão; S R Oliveira; A C S A Herrera; A L Cecchini; R Cecchini
Journal:  Age (Dordr)       Date:  2012-05-28

2.  Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.

Authors:  Louis M Chu; Michael P Robich; Cesario Bianchi; Jun Feng; Yuhong Liu; Shu-Hua Xu; Thomas Burgess; Frank W Sellke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-28       Impact factor: 4.733

Review 3.  Mood disorders and obesity: understanding inflammation as a pathophysiological nexus.

Authors:  Joanna K Soczynska; Sidney H Kennedy; Hanna O Woldeyohannes; Samantha S Liauw; Mohammad Alsuwaidan; Christina Y Yim; Roger S McIntyre
Journal:  Neuromolecular Med       Date:  2010-12-17       Impact factor: 3.843

4.  Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats.

Authors:  L-W Fan; A Kaizaki; L-T Tien; Y Pang; S Tanaka; S Numazawa; A J Bhatt; Z Cai
Journal:  Neuroscience       Date:  2013-02-26       Impact factor: 3.590

5.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

6.  Low fish oil intake improves insulin sensitivity, lipid profile and muscle metabolism on insulin resistant MSG-obese rats.

Authors:  Ricardo K Yamazaki; Gleisson A P Brito; Isabela Coelho; Danielle C T Pequitto; Adriana A Yamaguchi; Gina Borghetti; Dalton Luiz Schiessel; Marcelo Kryczyk; Juliano Machado; Ricelli E R Rocha; Julia Aikawa; Fabiola Iagher; Katya Naliwaiko; Ricardo A Tanhoffer; Everson A Nunes; Luiz Claudio Fernandes
Journal:  Lipids Health Dis       Date:  2011-04-28       Impact factor: 3.876

7.  Monosodium glutamate neonatal treatment induces cardiovascular autonomic function changes in rodents.

Authors:  Signorá Peres Konrad; Vera Farah; Bruno Rodrigues; Rogério Brandão Wichi; Ubiratan Fabres Machado; Heno Ferreira Lopes; Beatriz D'Agord Schaan; Kátia De Angelis; Maria Cláudia Irigoyen
Journal:  Clinics (Sao Paulo)       Date:  2012-10       Impact factor: 2.365

8.  Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide.

Authors:  Asuka Kaizaki; Lu-Tai Tien; Yi Pang; Zhengwei Cai; Sachiko Tanaka; Satoshi Numazawa; Abhay J Bhatt; Lir-Wan Fan
Journal:  J Neuroinflammation       Date:  2013-04-05       Impact factor: 8.322

9.  Glutamate-induced obesity leads to decreased sperm reserves and acceleration of transit time in the epididymis of adult male rats.

Authors:  Glaura Sa Fernandes; Arielle C Arena; Kleber E Campos; Gustavo T Volpato; Janete A Anselmo-Franci; Débora C Damasceno; Wilma G Kempinas
Journal:  Reprod Biol Endocrinol       Date:  2012-12-05       Impact factor: 5.211

10.  Metabolic syndrome agravates cardiovascular, oxidative and inflammatory dysfunction during the acute phase of Trypanosoma cruzi infection in mice.

Authors:  Bruno Fernando Cruz Lucchetti; Natalia Boaretto; Fernanda Novi Cortegoso Lopes; Aparecida Donizette Malvezi; Maria Isabel Lovo-Martins; Vera Lúcia Hideko Tatakihara; Victor Fattori; Rito Santo Pereira; Waldiceu Aparecido Verri; Eduardo Jose de Almeida Araujo; Phileno Pinge-Filho; Marli Cardoso Martins-Pinge
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.